Cargando…

Secondary Hypogammaglobulinemia After Rituximab for Neuromyelitis Optica: A Case Report

A 17-year-old male with history of neuromyelitis optica and seizures presented to the pulmonology clinic for evaluation of recurrent pneumonias. He had received rituximab for the past 6 years. Over the past 2 years, he experienced four episodes of pneumonia. In between these episodes, he would impro...

Descripción completa

Detalles Bibliográficos
Autores principales: Farhat, Lara, Dara, Jasmeen, Duberstein, Susan, De, Aliva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5948191/
https://www.ncbi.nlm.nih.gov/pubmed/29752554
http://dx.doi.org/10.1007/s40800-018-0087-y
_version_ 1783322496258277376
author Farhat, Lara
Dara, Jasmeen
Duberstein, Susan
De, Aliva
author_facet Farhat, Lara
Dara, Jasmeen
Duberstein, Susan
De, Aliva
author_sort Farhat, Lara
collection PubMed
description A 17-year-old male with history of neuromyelitis optica and seizures presented to the pulmonology clinic for evaluation of recurrent pneumonias. He had received rituximab for the past 6 years. Over the past 2 years, he experienced four episodes of pneumonia. In between these episodes, he would improve briefly but continued to have daily cough that was productive with yellow phlegm. He also had recurrent rhinitis and sinusitis despite multiple antibiotic courses. Review of chest X-rays revealed localized right middle lobe and right lower lobe infiltrates. An extensive workup was performed, including computed tomography (CT) of the chest and bronchoscopy to rule out congenital lesions of the right lung and foreign body aspiration. Chest CT showed right lower lobe bronchiectasis. Flexible bronchoscopy with bronchoalveolar lavage showed normal anatomy with thick mucus secretions in the right lower lobe. Immunologic evaluation was performed and revealed low levels of immunoglobulin (Ig)-G, IgM, and IgA, which had declined since initiation of rituximab. Lymphocyte subset testing was remarkable for low cluster of differentiation (CD)-19. He was referred to allergy and immunology and was initiated on immunoglobulin-replacement therapy (IGRT) for acquired hypogammaglobulinemia secondary to rituximab. There was marked clinical improvement after initiation of IGRT.
format Online
Article
Text
id pubmed-5948191
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-59481912018-05-17 Secondary Hypogammaglobulinemia After Rituximab for Neuromyelitis Optica: A Case Report Farhat, Lara Dara, Jasmeen Duberstein, Susan De, Aliva Drug Saf Case Rep Case Report A 17-year-old male with history of neuromyelitis optica and seizures presented to the pulmonology clinic for evaluation of recurrent pneumonias. He had received rituximab for the past 6 years. Over the past 2 years, he experienced four episodes of pneumonia. In between these episodes, he would improve briefly but continued to have daily cough that was productive with yellow phlegm. He also had recurrent rhinitis and sinusitis despite multiple antibiotic courses. Review of chest X-rays revealed localized right middle lobe and right lower lobe infiltrates. An extensive workup was performed, including computed tomography (CT) of the chest and bronchoscopy to rule out congenital lesions of the right lung and foreign body aspiration. Chest CT showed right lower lobe bronchiectasis. Flexible bronchoscopy with bronchoalveolar lavage showed normal anatomy with thick mucus secretions in the right lower lobe. Immunologic evaluation was performed and revealed low levels of immunoglobulin (Ig)-G, IgM, and IgA, which had declined since initiation of rituximab. Lymphocyte subset testing was remarkable for low cluster of differentiation (CD)-19. He was referred to allergy and immunology and was initiated on immunoglobulin-replacement therapy (IGRT) for acquired hypogammaglobulinemia secondary to rituximab. There was marked clinical improvement after initiation of IGRT. Springer International Publishing 2018-05-11 /pmc/articles/PMC5948191/ /pubmed/29752554 http://dx.doi.org/10.1007/s40800-018-0087-y Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Case Report
Farhat, Lara
Dara, Jasmeen
Duberstein, Susan
De, Aliva
Secondary Hypogammaglobulinemia After Rituximab for Neuromyelitis Optica: A Case Report
title Secondary Hypogammaglobulinemia After Rituximab for Neuromyelitis Optica: A Case Report
title_full Secondary Hypogammaglobulinemia After Rituximab for Neuromyelitis Optica: A Case Report
title_fullStr Secondary Hypogammaglobulinemia After Rituximab for Neuromyelitis Optica: A Case Report
title_full_unstemmed Secondary Hypogammaglobulinemia After Rituximab for Neuromyelitis Optica: A Case Report
title_short Secondary Hypogammaglobulinemia After Rituximab for Neuromyelitis Optica: A Case Report
title_sort secondary hypogammaglobulinemia after rituximab for neuromyelitis optica: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5948191/
https://www.ncbi.nlm.nih.gov/pubmed/29752554
http://dx.doi.org/10.1007/s40800-018-0087-y
work_keys_str_mv AT farhatlara secondaryhypogammaglobulinemiaafterrituximabforneuromyelitisopticaacasereport
AT darajasmeen secondaryhypogammaglobulinemiaafterrituximabforneuromyelitisopticaacasereport
AT dubersteinsusan secondaryhypogammaglobulinemiaafterrituximabforneuromyelitisopticaacasereport
AT dealiva secondaryhypogammaglobulinemiaafterrituximabforneuromyelitisopticaacasereport